400 related articles for article (PubMed ID: 23259931)
1. Perampanel, a novel, non-competitive, selective AMPA receptor antagonist as adjunctive therapy for treatment-resistant partial-onset seizures.
Rektor I
Expert Opin Pharmacother; 2013 Feb; 14(2):225-35. PubMed ID: 23259931
[TBL] [Abstract][Full Text] [Related]
2. Perampanel, a selective, noncompetitive α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor antagonist, as adjunctive therapy for refractory partial-onset seizures: interim results from phase III, extension study 307.
Krauss GL; Perucca E; Ben-Menachem E; Kwan P; Shih JJ; Squillacote D; Yang H; Gee M; Zhu J; Laurenza A
Epilepsia; 2013 Jan; 54(1):126-34. PubMed ID: 22905878
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of adjunctive perampanel in patients with refractory partial-onset seizures: results of randomized global phase III study 305.
French JA; Krauss GL; Steinhoff BJ; Squillacote D; Yang H; Kumar D; Laurenza A
Epilepsia; 2013 Jan; 54(1):117-25. PubMed ID: 22905857
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of adjunctive perampanel for the treatment of refractory partial seizures: a pooled analysis of three phase III studies.
Steinhoff BJ; Ben-Menachem E; Ryvlin P; Shorvon S; Kramer L; Satlin A; Squillacote D; Yang H; Zhu J; Laurenza A
Epilepsia; 2013 Aug; 54(8):1481-9. PubMed ID: 23663001
[TBL] [Abstract][Full Text] [Related]
5. Randomized phase III study 306: adjunctive perampanel for refractory partial-onset seizures.
Krauss GL; Serratosa JM; Villanueva V; Endziniene M; Hong Z; French J; Yang H; Squillacote D; Edwards HB; Zhu J; Laurenza A
Neurology; 2012 May; 78(18):1408-15. PubMed ID: 22517103
[TBL] [Abstract][Full Text] [Related]
6. Concentration-effect relationships with perampanel in patients with pharmacoresistant partial-onset seizures.
Gidal BE; Ferry J; Majid O; Hussein Z
Epilepsia; 2013 Aug; 54(8):1490-7. PubMed ID: 23772853
[TBL] [Abstract][Full Text] [Related]
7. Development of perampanel in epilepsy.
Satlin A; Kramer LD; Laurenza A
Acta Neurol Scand Suppl; 2013; (197):3-8. PubMed ID: 23480150
[TBL] [Abstract][Full Text] [Related]
8. Perampanel: a novel antiepileptic for the adjunctive treatment of refractory partial onset seizures.
Owen RT
Drugs Today (Barc); 2013 Jan; 49(1):23-31. PubMed ID: 23362493
[TBL] [Abstract][Full Text] [Related]
9. Perampanel in the treatment of focal and idiopathic generalized epilepsies and of status epilepticus.
Strzelczyk A; Willems LM; Willig S; Rosenow F; Bauer S
Expert Rev Clin Pharmacol; 2015; 8(6):733-40. PubMed ID: 26436331
[TBL] [Abstract][Full Text] [Related]
10. The discovery and development of perampanel for the treatment of epilepsy.
Hanada T
Expert Opin Drug Discov; 2014 Apr; 9(4):449-58. PubMed ID: 24559052
[TBL] [Abstract][Full Text] [Related]
11. Perampanel, an antagonist of α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptors, for the treatment of epilepsy: studies in human epileptic brain and nonepileptic brain and in rodent models.
Zwart R; Sher E; Ping X; Jin X; Sims JR; Chappell AS; Gleason SD; Hahn PJ; Gardinier K; Gernert DL; Hobbs J; Smith JL; Valli SN; Witkin JM
J Pharmacol Exp Ther; 2014 Oct; 351(1):124-33. PubMed ID: 25027316
[TBL] [Abstract][Full Text] [Related]
12. Perampanel: a novel, orally active, noncompetitive AMPA-receptor antagonist that reduces seizure activity in rodent models of epilepsy.
Hanada T; Hashizume Y; Tokuhara N; Takenaka O; Kohmura N; Ogasawara A; Hatakeyama S; Ohgoh M; Ueno M; Nishizawa Y
Epilepsia; 2011 Jul; 52(7):1331-40. PubMed ID: 21635236
[TBL] [Abstract][Full Text] [Related]
13. Tolerability and safety of perampanel: two randomized dose-escalation studies.
Krauss GL; Bar M; Biton V; Klapper JA; Rektor I; Vaiciene-Magistris N; Squillacote D; Kumar D
Acta Neurol Scand; 2012 Jan; 125(1):8-15. PubMed ID: 21883097
[TBL] [Abstract][Full Text] [Related]
14. Lack of effect of perampanel on QT interval duration: Results from a thorough QT analysis and pooled partial seizure Phase III clinical trials.
Yang H; Laurenza A; Williams B; Patten A; Hussein Z; Ferry J
Epilepsy Res; 2015 Aug; 114():122-30. PubMed ID: 26088895
[TBL] [Abstract][Full Text] [Related]
15. Perampanel as monotherapy and adjunctive therapy for focal onset seizures, focal to bilateral tonic-clonic seizures and as adjunctive therapy of generalized onset tonic-clonic seizures.
Tyrlikova I; Brazdil M; Rektor I; Tyrlik M
Expert Rev Neurother; 2019 Jan; 19(1):5-16. PubMed ID: 30560703
[No Abstract] [Full Text] [Related]
16. Adjunctive perampanel in adolescents with inadequately controlled partial-onset seizures: A randomized study evaluating behavior, efficacy, and safety.
Lagae L; Villanueva V; Meador KJ; Bagul M; Laurenza A; Kumar D; Yang H
Epilepsia; 2016 Jul; 57(7):1120-9. PubMed ID: 27221398
[TBL] [Abstract][Full Text] [Related]
17. [Perampanel in treatment of refractory partial epilepsy in adolescents and adults: results of international multicenter randomized, double-blind, placebo-controlled phase III studies].
Belousova ED
Zh Nevrol Psikhiatr Im S S Korsakova; 2014; 114(8):32-8. PubMed ID: 25345628
[TBL] [Abstract][Full Text] [Related]
18. Perampanel: expanding therapeutic options for patients with medically refractory secondary generalized convulsive seizures.
Ko D; Ramsay RE
Acta Neurol Scand Suppl; 2013; (197):36-43. PubMed ID: 23480155
[TBL] [Abstract][Full Text] [Related]
19. Perampanel for epilepsy with partial-onset seizures: a pharmacokinetic and pharmacodynamic evaluation.
Schulze-Bonhage A
Expert Opin Drug Metab Toxicol; 2015; 11(8):1329-37. PubMed ID: 26111428
[TBL] [Abstract][Full Text] [Related]
20. Perampanel: as adjunctive therapy in patients with partial-onset seizures.
Plosker GL
CNS Drugs; 2012 Dec; 26(12):1085-96. PubMed ID: 23179642
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]